BPC-157 + TB-500 Stack: Research Overview και Reported Ranges
TB-500 (Thymosin β4) promotes angiogenesis and cell migration. BPC-157 accelerates musculoskeletal healing via growth factors. The combination aims to provide synergistic support for tissue repair.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Canonical stack overview
This canonical stack hub presents BPC-157 and TB-500 as an educational research reference. It is designed to explain literature-derived context, concentration math and evidence limitations, not to provide medical advice, treatment guidance or human-use instructions.
Short answer
- Why they appear together: BPC-157 and TB-500 are often discussed together in recovery peptide stack research because they represent different tissue-model mechanisms.
- Different mechanistic angles: BPC-157 is discussed around VEGF/NO signaling and fibroblast migration; TB-500 is discussed around thymosin beta-4 context, actin regulation and cell migration.
- Reported ranges are not recommendations: Protocol-format numbers are educational arithmetic examples only, not dosing instructions.
- Reconstitution and units: Any reconstitution, mcg per unit or U-100 unit discussion should be read only as concentration math in an RUO context.
Mechanism comparison
BPC-157
- Angiogenesis research context and VEGF-associated signaling.
- Nitric oxide (NO) pathway discussion in preclinical models.
- Fibroblast migration and tissue-model endpoint literature.
- Non-clinical overview only; no therapeutic outcome promise.
TB-500
- Thymosin beta-4 research context and peptide-fragment discussion.
- Actin regulation and cell-migration model literature.
- Inflammatory signaling and tissue-repair model endpoints.
- Model-specific interpretation only; no human-use guidance.
Reported ranges and arithmetic context
- Reported ranges shown in protocol-format examples are for educational research arithmetic only.
- They should be interpreted as concentration and planning math, not as a dosing instruction, research schedule instruction or clinical protocol.
- Use the calculator and syringe-units guide to understand mg/mL, mcg per unit and U-100 conversions without turning the examples into instructions.
Safety and evidence limitations
- Human evidence for the exact BPC-157 + TB-500 combination remains limited and should not be generalized from model-specific findings.
- This page is RUO-only educational content, not medical advice, not a treatment recommendation and not a human-use instruction.
- Storage, sterility and evidence grading should be reviewed separately before interpreting any research arithmetic.
Related educational links
FAQ
What is the BPC-157 + TB-500 stack?
It is an educational research-reference page for two peptides that are often discussed together in tissue-model and recovery-research contexts. It is not a clinical protocol.
Why are BPC-157 and TB-500 discussed together?
They are discussed together because BPC-157 and TB-500 represent different mechanistic angles, including VEGF/NO signaling, fibroblast migration, actin regulation and cell-migration models.
Is there a dosing instruction?
No. Any reported ranges are educational research arithmetic examples only and are not dosing instructions, research schedule instructions or human-use instructions.
Is this a therapeutic protocol?
No. AllPeptides.eu presents this route as a non-clinical RUO overview and not as medical advice, therapy guidance or a treatment recommendation.
How does this connect to reconstitution math?
The calculator, syringe-units guide and reconstitution guide explain concentration, mcg per unit and U-100 conversions as arithmetic references only.
What are the human evidence limitations?
Human evidence for the exact combination remains limited, and findings from model systems should be interpreted cautiously within a research-only framework.
How It Works
TB-500 mimics endogenous Thymosin β4, regulating inflammation and activating PI3K/Akt and Notch pathways for angiogenesis/cell migration. BPC-157 upregulates angiogenic pathways (VEGF) and neutralizes inflammatory cytokines. The combination aims to provide: TB-500 for systemic tissue restoration + BPC-157 for localized healing support.
Quick Start
- TB-500: Add 2.0 mL BAC water → 2.5 mg/mL.
- BPC-157: Add 2.0 mL BAC water → 2.5 mg/mL.
- TB-500: 1,250 mcg (50 units) 2×/wk (wks 1–4), then 1×/wk (wks 5–12).
- BPC-157: 250–500 mcg (10–20 units) 1×/day, titrated over 12 wks.
- Storage: Lyophilized: 2–8 °C; reconstituted: 2–8 °C, use within ~30 days.
TB-500 & BPC-157 Dosing (2 mL = 2.5 mg/mL per vial)
Route: Subcutaneously | Frequency: TB-500: 2×/wk → 1×/wk | BPC-157: 1×/day
| Week | Dose | Units (per injection) |
|---|---|---|
| — TB-500 — | ||
| Weeks 1–4 (Loading) | 1,250 mcg (1.25 mg) | 50 units (0.50 mL) — 2×/wk |
| Weeks 5–12 (Maintenance) | 1,250 mcg (1.25 mg) | 50 units (0.50 mL) — 1×/wk |
| — BPC-157 — | ||
| Weeks 1–2 | 250 mcg/day | 10 units (0.10 mL) |
| Weeks 3–8 | 500 mcg/day | 20 units (0.20 mL) |
| Weeks 9–12 (Taper) | 250 mcg/day | 10 units (0.10 mL) |
The TB-500 loading phase (2×/wk) ensures tissue saturation. BPC-157 is preferably administered near the site of injury.
Related compounds
Reconstitution Steps
Dilution Selection
Peptides come in 3 mL, 5 mL or 10 mL vials. If your vial is smaller, the water amount adjusts automatically.
TB-500 (5 mg)
BPC-157 (5 mg)
⚠️ Units change depending on BAC water — always verify before administration. Based on
- TB-500: Withdraw 2.0 mL BAC water → inject slowly → swirl gently → 2.5 mg/mL.
- BPC-157: Withdraw 2.0 mL BAC water → inject slowly → swirl gently → 2.5 mg/mL.
- Note the date; refrigerate at 2–8 °C, protect from light.
Protocol Overview
- Goal: Tissue repair, inflammation reduction, accelerated recovery.
- Schedule: TB-500 2×/wk (loading) → 1×/wk; BPC-157 daily.
- Range: TB-500: 1,250 mcg/injection; BPC-157: 250–500 mcg/day.
Dosing Protocol
- TB-500 Loading: 1,250 mcg 2×/wk for 4 wks (~2.5 mg/wk).
- TB-500 Maintenance: 1,250 mcg 1×/wk (wks 5–12).
- BPC-157: 250 mcg/day (2 wks) → 500 mcg/day (wks 3–8) → 250 mcg/day (wks 9–12).
- Timing: BPC-157 near the injury site if possible.
- Break between cycles: After the cycle, a 2–4 week break is recommended before repeating. This pause helps prevent tolerance to BPC-157 and TB-500.
Washout & Cycle Restart
When can I restart?
After the cycle, a 2–4 week break is recommended before repeating. This pause helps prevent tolerance to BPC-157 and TB-500.
Minimum wait period: 2 weeks
Storage Instructions
- Lyophilized: 2–8 °C; long-term at −20 °C.
- Reconstituted: 2–8 °C; use within ~30 days; do not freeze.
Important Notes
- BPC-157: inject near the injured tissue if possible.
- Can be administered on the same day but at different sites.
Potential Benefits & Side Effects
Potential Benefits:
- TB-500: Accelerated healing, reduced fibrosis (preclinical studies).
- BPC-157: Repair of tendons, ligaments, muscles, and bones with no reported toxicity.
- Combination: Complementary mechanisms of action (systemic + local).
Potential Side Effects:
- Generally well-tolerated in research protocols.
- Mild injection site reactions (redness, itching).
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical concern: angiogenesis & oncogenesis
BPC-157 promotes angiogenesis (VEGF upregulation). May theoretically enhance blood supply to existing tumors. No clinical data in humans.
📄 J Physiol Pharmacol 2010Theoretical concern: angiogenesis
Thymosin β4 regulates angiogenesis and cell migration. Theoretical concern that it may favor growth of existing tumors, though no clinical evidence exists.
📄 Ann NY Acad Sci 2007References
- Front Endocrinol (2021) — Thymosin β4: function & applications
View Source - Ann NY Acad Sci — Thymosin β4 in cardiovascular repair
View Source - Front Pharmacol (2022) — BPC-157: pharmacokinetics & metabolism
View Source - HSS Journal (2025) — BPC-157 in Sports Medicine: A Systematic Review
View Source
Recommended Supplements
Curcumin (Turmeric Extract)
Collagen Peptides
🧬 General Wellness
Multivitamin (High-Quality)
Magnesium Glycinate
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Probiotics (Multi-Strain)
Electrolytes (Na, K, Mg)
Liver Support (NAC / Milk Thistle)
External Sources & Regulatory Status
Regulatory Approvals
Research-only — No regulatory approval (extensive preclinical research)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →